Identifying biomarkers to assess relapse risk in clear cell kidney cancer
Combination of Transcriptomic and Metallomic Biomarkers for Risk Assessment in Locoregional Clear Cell Renal Cell Carcinoma
This study is looking for better ways to predict if patients with clear cell kidney cancer might have a relapse after surgery, using special tests on their tumors to help doctors decide who might need extra treatment.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10898042 on NIH RePORTER |
What this research studies
This research aims to develop new methods for predicting the risk of relapse in patients with clear cell renal cell carcinoma (ccRCC) after surgery. By analyzing specific genetic and metallomic markers, the study seeks to categorize tumors into high-risk and low-risk groups for recurrence. This approach could help tailor adjuvant therapies more effectively to those who need them most. Patients will be evaluated based on their tumor characteristics and biological markers to determine their risk levels.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with localized or locally advanced clear cell renal cell carcinoma who have undergone surgical resection.
Not a fit: Patients with metastatic clear cell renal cell carcinoma or those who have not undergone surgery may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for patients with clear cell kidney cancer, potentially reducing the risk of cancer recurrence.
How similar studies have performed: Other research has shown promise in using biomarkers for cancer risk assessment, indicating that this approach could be a valuable advancement in the field.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Gulati, Shuchi — University of California at Davis
- Study coordinator: Gulati, Shuchi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.